Abstract Number: 2792 • 2019 ACR/ARP Annual Meeting
The Need for Personalized, Non-Pharmacological Intervention Programmes in Autoimmune Connective Tissue Disorders: Results of a EULAR-Funded Scoping Review with a Nested, Descriptive Meta-Analysis
Background/Purpose: Autoimmune Connective Tissue Disorders (CTDs), including Mixed Connective Tissue Disorders (MCTD), systemic sclerosis (SSc) and systemic lupus erythematous (SLE) can lead to Raynaud phenomenon,…Abstract Number: 75 • 2019 ACR/ARP Annual Meeting
Microglia-Specific Transcriptional Signatures Correlate with Behavioral Deficits in ‘Neuropsychiatric Symptoms of Systemic Lupus Erythematosus’
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune syndrome affecting multiple organs, including the brain. More than 50% of patients experience neuropsychiatric symptoms of…Abstract Number: 642 • 2019 ACR/ARP Annual Meeting
Complement Deposition C4d on Platelets Is Associated with Vascular Events in Systemic Lupus Erythematosus
Background/Purpose: Complement components, including C4d, can be detected on the surface of activated platelets and they have been associated with vascular disease in systemic lupus…Abstract Number: 703 • 2019 ACR/ARP Annual Meeting
Prior Knowledge Feature Reduction Improves Performance in a Machine Learning Model of Systemic Lupus Erythematosus Flare Status Using Serum Proteomics
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic auto-immune condition characterized by systemic inflammation that can exacerbate (flare) unpredictably, causing widespread organ damage. Identification of…Abstract Number: 1021 • 2019 ACR/ARP Annual Meeting
Anti-IFNAR Treatment Does Not Reverse Neuropsychiatric Disease in MRL/lpr Lupus Mice
Background/Purpose: Many systemic lupus erythematosus patients display a type I interferon (IFN) signature, and IFNα levels and gene signatures have been positively correlated with disease…Abstract Number: 1152 • 2019 ACR/ARP Annual Meeting
Low Rates of Bone Mineral Density Testing by Rheumatologists in Patients with Systemic Lupus Erythematosus and Glucocorticoid Therapy
Background/Purpose: Patients with systemic lupus erythematosus (SLE) are at an increased risk of developing osteoporosis and clinical fractures compared to healthy controls. Bone loss in…Abstract Number: 1581 • 2019 ACR/ARP Annual Meeting
Impact of Diabetes on Risk of End Stage Renal Disease in Danish Nationwide Cohort of Newly Diagnosed Patients with Systemic Lupus Erythematosus
Background/Purpose: Risk of end stage renal disease (ESRD) is increased in patients with systemic lupus erythematosus (SLE). Due to lifestyle –related risk factors, inflammation, and…Abstract Number: 1622 • 2019 ACR/ARP Annual Meeting
Cognitive Impairments in SLE Negatively Related to Participation and Quality of Life: A Systematic Review
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease affecting multiple organ systems. Approximately 33 to 43% of individuals with SLE experience cognitive impairments…Abstract Number: 1865 • 2019 ACR/ARP Annual Meeting
Improving Lupus Care Index Documentation in Patients with Childhood-Onset Systemic Lupus Erythematosus (cSLE)
Background/Purpose: Systemic lupus erythematosus (SLE) affects both adults and children with an estimated prevalence in children of 8/100,000. More than 1000 deaths related to SLE…Abstract Number: 2109 • 2019 ACR/ARP Annual Meeting
Are Immunosuppressants a Risk Factor Associated with Mycobacterium Tuberculosis Infection in Colombian Patients with Systemic Lupus Erythematosus? A Case-control Study
Background/Purpose: Tuberculosis (TB) infection is an important cause of morbidity and mortality in systemic lupus erythematosus (SLE) patients, especially in developing countries. Previous studies have…Abstract Number: 2524 • 2019 ACR/ARP Annual Meeting
24-Month Outcomes Associated with Belimumab in Black/African-American Patients with Systemic Lupus Erythematosus in a Clinical Practice Setting in the United States
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by diverse clinical manifestations and organ damage accrual. Black/African-American (B/AA) race is associated with…Abstract Number: 2561 • 2019 ACR/ARP Annual Meeting
Deep Remission During Induction Therapy for Lupus Nephritis Prevents Damage Accrual and Associates with the Baseline Proportions of Peripheral Treg, CD8+ T Cells, and NKT-like Cells
Background/Purpose: chievement of renal remission has been the target of the induction therapy in patients with active lupus nephritis (LN). Deep remission (DR) defined as…Abstract Number: 2795 • 2019 ACR/ARP Annual Meeting
Patterns of Ambulatory Health Care Utilization and Medication Adherence Among Transition-Age Youth with Systemic Lupus Erythematosus
Background/Purpose: Youth with child-onset systemic lupus erythematosus (SLE) transitioning from pediatric to adult health care systems may be at higher risk for poor outcomes than…Abstract Number: 76 • 2019 ACR/ARP Annual Meeting
Effect of Ifnα and Costimulatory Blockade on Brain Infiltration in a Model of ‘Neuropsychiatric Symptoms of Systemic Lupus Erythematosus’
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease that affects many end organs including the brain. Despite a prevalence of over 50% in…Abstract Number: 646 • 2019 ACR/ARP Annual Meeting
A Meta-Analysis of Anti-Ribosomal P Autoantibodies in Systemic Lupus Erythematosus: A Misunderstood Autoantibody
Background/Purpose: Anti-ribosomal P (Rib-P) antibodies have become known as a highly specific biomarker for the diagnosis of SLE and potentially a biomarker for neuropsychiatric SLE…
- « Previous Page
- 1
- …
- 135
- 136
- 137
- 138
- 139
- …
- 150
- Next Page »